JP7247092B2 - キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 - Google Patents

キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 Download PDF

Info

Publication number
JP7247092B2
JP7247092B2 JP2019537063A JP2019537063A JP7247092B2 JP 7247092 B2 JP7247092 B2 JP 7247092B2 JP 2019537063 A JP2019537063 A JP 2019537063A JP 2019537063 A JP2019537063 A JP 2019537063A JP 7247092 B2 JP7247092 B2 JP 7247092B2
Authority
JP
Japan
Prior art keywords
triazolo
dimethyl
quinoxalin
piperidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504139A5 (cg-RX-API-DMAC7.html
JP2020504139A (ja
Inventor
蔡遂雄
田野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Impact Therapeutics Shanghai Inc
Original Assignee
Impact Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Therapeutics Shanghai Inc filed Critical Impact Therapeutics Shanghai Inc
Publication of JP2020504139A publication Critical patent/JP2020504139A/ja
Publication of JP2020504139A5 publication Critical patent/JP2020504139A5/ja
Application granted granted Critical
Publication of JP7247092B2 publication Critical patent/JP7247092B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019537063A 2017-01-09 2018-01-09 キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 Active JP7247092B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710014520.1 2017-01-09
CN201710014520 2017-01-09
PCT/CN2018/071851 WO2018127195A1 (zh) 2017-01-09 2018-01-09 取代的稠合杂芳基化合物作为激酶抑制剂及其应用

Publications (3)

Publication Number Publication Date
JP2020504139A JP2020504139A (ja) 2020-02-06
JP2020504139A5 JP2020504139A5 (cg-RX-API-DMAC7.html) 2021-02-25
JP7247092B2 true JP7247092B2 (ja) 2023-03-28

Family

ID=62789082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019537063A Active JP7247092B2 (ja) 2017-01-09 2018-01-09 キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途

Country Status (8)

Country Link
US (1) US10874670B2 (cg-RX-API-DMAC7.html)
EP (1) EP3567041B1 (cg-RX-API-DMAC7.html)
JP (1) JP7247092B2 (cg-RX-API-DMAC7.html)
KR (1) KR102660196B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167941B (cg-RX-API-DMAC7.html)
AU (1) AU2018206111B2 (cg-RX-API-DMAC7.html)
CA (1) CA3049608A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018127195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3823971T (pt) 2018-07-20 2022-10-26 Gruenenthal Gmbh Derivados substituídos de triazolo quinoxalina
TWI811400B (zh) * 2018-07-20 2023-08-11 德商歌林達有限公司 經進一步取代之三唑并喹噁啉衍生物
WO2021004482A1 (zh) * 2019-07-10 2021-01-14 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN119215050A (zh) * 2019-09-12 2024-12-31 上海瑛派药业有限公司 取代的咪唑并喹喔啉化合物在制备抗癌症药物中的应用
EP4084495A4 (en) 2020-04-29 2023-07-12 Shenzhen Shokz Co., Ltd. Acoustic device, and magnetic circuit assembly thereof
KR102458689B1 (ko) * 2020-07-08 2022-10-25 원광대학교산학협력단 피페리딘 화합물 및 이의 제조 방법
KR20240001206A (ko) * 2021-04-26 2024-01-03 오하이오 스테이트 이노베이션 파운데이션 지질 나노물질 및 이의 용도
KR20250165317A (ko) 2023-01-18 2025-11-25 안텐진 디스커버리 리미티드 Prmt5 억제 화합물 및 그의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
JP2013537204A (ja) 2010-09-16 2013-09-30 ハチソン メディファーマ リミテッド 縮合ヘテロアリールおよびその使用
WO2015170081A1 (en) 2014-05-08 2015-11-12 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
DE102010025786A1 (de) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
CN103124731B (zh) * 2010-09-16 2016-01-20 和记黄埔医药(上海)有限公司 稠合的杂芳基化合物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
JP2013537204A (ja) 2010-09-16 2013-09-30 ハチソン メディファーマ リミテッド 縮合ヘテロアリールおよびその使用
WO2015170081A1 (en) 2014-05-08 2015-11-12 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Also Published As

Publication number Publication date
EP3567041C0 (en) 2023-12-27
EP3567041A9 (en) 2022-04-20
US10874670B2 (en) 2020-12-29
WO2018127195A1 (zh) 2018-07-12
CA3049608A1 (en) 2018-07-12
KR20190098266A (ko) 2019-08-21
US20190358225A1 (en) 2019-11-28
EP3567041A4 (en) 2020-08-05
AU2018206111A1 (en) 2019-08-22
EP3567041B1 (en) 2023-12-27
JP2020504139A (ja) 2020-02-06
EP3567041A1 (en) 2019-11-13
CN110167941A (zh) 2019-08-23
AU2018206111B2 (en) 2022-07-21
CN110167941B (zh) 2023-04-04
KR102660196B1 (ko) 2024-04-24

Similar Documents

Publication Publication Date Title
JP7247092B2 (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
JP7240784B2 (ja) 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物
JP7721501B2 (ja) Cd38の阻害剤としてのヘテロ二環式アミド
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
CN119591600A (zh) 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US20240409538A1 (en) Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof
WO2021043208A1 (en) 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
US11547703B2 (en) Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
CN114026097B (zh) 取代的吡唑并喹唑啉酮化合物及其应用
WO2024083237A1 (en) Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
US20240124464A1 (en) Substituted fused bicyclic compound as kinase inhibitor and use thereof
CN114787162B (zh) 取代的咪唑并喹喔啉化合物及其应用
WO2024179547A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
CN112480120A (zh) 取代的咪唑并喹喔啉化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230315

R150 Certificate of patent or registration of utility model

Ref document number: 7247092

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150